ASCO: Antibody Shows Promise in Ovarian Cancer

posted on Jun 10 by MedPage Today OB/Gyn in the Uncategorized category CHICAGO (MedPage Today) -- Women with relapsed, platinum-sensitive ovarian cancer had a 70% overall response rate to treatment with a taxane plus an antifolate receptor antibody, data from a small clinical trial showed.